Home › Search
Search
314 results for "lecanemab".
Research summaries 285
Showing the best 200 of 285, 121–130, page 13 of 20. Filter these by subject, year and score in the research library →
-
Research summaries · alzhub.org/study/lecanemab-autorizado-para-tratamiento-del-alzheimer-en-pacientes-que-d2104574
… marketing authorization for lecanemab only in Alzheimer's patients who have one or no copies of the ApoE4 gene. This population is less likely to experience ARIA, a serious adverse reaction involving brain swelling and possible …
-
Clonal expansion of cytotoxic CD8⁺ T cells in lecanemab-associated ARIAResearch summary
Research summaries · alzhub.org/study/clonal-expansion-of-cytotoxic-cd8-t-cells-in-lecanemab-associated-aria-41617706
Amyloid-related imaging abnormalities (ARIA) are the principal safety concern limiting anti-amyloid therapies for Alzheimer's disease, yet their biology remains unclear. Here we show, through multi-omic profiling of peripheral …
-
APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD studyResearch summary
Research summaries · alzhub.org/study/apoe-guided-lecanemab-dosing-dissociates-aria-e-from-aria-h-the-k-42642841
ARIA-E incidence was 2.0% in non-carriers and 6.2% in εε4/εε4 homozygotes (εε4/εε4-versus-non-carrier OR 3.25, versus 8.49 in Clarity AD and 8.32 in Japan post-marketing surveillance). Any ARIA-H was independently predicted by …
-
Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatmentResearch summary
Research summaries · alzhub.org/study/heterogeneity-in-plasma-p-tau217-response-and-its-association-with-42535277
Plasma p-tau217 levels decreased significantly from 3 months, with the greatest decline between 3 and 6 months, followed by a plateau. Two distinct trajectory groups were identified. Patients in the greater reduction group showed …
-
Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical CenterResearch summary
Research summaries · alzhub.org/study/initial-experience-with-lecanemab-and-lessons-learned-in-71-patients-39559868
Results The mean age was 72 years (49-90 years), and 44 (62%) patients were female. Results The mean age was 72 years (49-90 years), and 44 (62%) patients were female. The journal of prevention of Alzheimer's disease 2024 …
-
Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42Research summary
Research summaries · alzhub.org/study/recalibrating-the-risk-benefit-profiles-of-lecanemab-and-donanemab-38701151
Three recent anti-amyloid-β antibody trials for Alzheimer's disease reported similar effect sizes, used non-reactive saline as placebo, and showed large numbers of adverse events including imaging anomalies (ARIA) that correlate …
-
Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemabResearch summary
Research summaries · alzhub.org/study/racial-and-ethnic-differences-in-plasma-p-tau217-ratio-biomarker-40861822
Among 6437 participants screened, with non-Hispanic (NH) White as the reference group, odds ratios of plasma ineligibility were 2.88 (95% confidence interval [CI]: 1.40-6.96) for Hispanic Black, 1.60 (95% CI: 1.33-1.92) for …
-
Research summaries · alzhub.org/study/eligibility-rates-among-racially-and-ethnically-diverse-us-37830926
Objective Many factors contribute to inadequate diversity in Alzheimer disease (AD) clinical trials. We evaluated eligibility rates among racial and ethnic groups at US sites in large global multisite trials in early AD. Methods …
-
Research summaries · alzhub.org/study/brain-amyloid-plaque-levels-affect-clinical-progression-in-alzheimer-41543367
Lecanemab is a humanized IgG1 monoclonal antibody binding with high affinity to protofibrils of amyloid-beta (Aβ) protein. In clinical studies, lecanemab has been shown to reduce amyloid markers in early symptomatic Alzheimer's …
-
Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysisResearch summary
Research summaries · alzhub.org/study/value-based-prices-of-emerging-disease-modifying-therapies-for-42125995
… value-based prices (VBPs) for lecanemab and donanemab across 174 countries. Methods The cost-effectiveness of lecanemab and donanemab was estimated using incremental cost and quality-adjusted life years (QALYs) compared to usual …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
28781 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.